Trial · NCT05846880
VitD3 Supplementation in Patients With Multiple Myeloma
NCT05846880, Early phase 1, Recruiting, Amany Keruakous, MD, MS.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. VitD3 Supplementation in Patients With Multiple Myeloma. Trials, record NCT05846880. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05846880
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- VitD3 Supplementation in Patients With Multiple Myeloma
- NCT number
- NCT05846880
- Status
- Recruiting
- Phases
- Early phase 1
- Enrollment
- 100 participants, estimated
- Lead sponsor
- Amany Keruakous, MD, MS.
- Conditions
- Multiple Myeloma
- Interventions
- Lenalidomide, Maintenance Vitamin D, No maintenance Vitamin D
- First posted
- 2023-05-06
- Last updated
- 2025-04-08
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | To describe the lymphocyte subset analysis for the two treatment arms at 120 days post autologous stem cell transplant [120 days] | 120 days | Evaluate absolute lymphocyte count and the difference in subset analysis (absolute CD4 count, absolute CD8 count) 120 days after ASCT |
| Secondary | 3 year progression free survival | 3 years | To report the 3-year progression-free survival for both treatment arms - maintenance Vitamin D vs. No maintnenace Vitamin D supplementation |
| Secondary | Overall Response Rate post 120 days of ASCT | 120 Days | report the overall response rate for both treatment arms 120 days after ASCT for adult patients with multiple myeloma. |
| Secondary | Overall Response Rate after transplantation | Two Years | To report the overall response rate for both treatment arms 2 years after transplantation |
| Secondary | 3 Year Overall Survival after transplantation | Three Years | To report the 3-year overall survival for the two treatment arms after transplantation. |
| Secondary | Minimal Residual Disease status | Randomization; 120 days after transplantation; two years after transplantation. | To report the minimal residual disease status for the two treatment arms at randomization, and within 120 days after transplantation and 2 years after transplantation. |
| Secondary | Vitamin D levels | Before autologous stem cell transplant; 120 days after transplantation; three years post-transplantation | To report the vitamin D levels between the two treatments arms before autologous stem cell transplant, within 120 days, and 3-years post-transplantation |
| Secondary | Adverse Event Reporting | Three years | To describe the adverse events for the two treatment arms |
| Secondary | Neutrophil and Platelet Engraftment and Transfusion Independence | After transplantation, an average of 30 days | Time to neutrophil and platelet engraftment as well as transfusion independence after transplantation |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05846880
GET https://conductscience.org/api/trials/v1/NCT05846880/registered